FutureLife Group expands its footprint in the UK through the strategic acquisition of Bristol Centre for Reproductive Medicine (BCRM)

Prague/Bristol, 31st October 2024 – FutureLife, a leading pan-European provider of fertility, IVF and genetics services, performing over 55,000 IVF cycles annually and backed by CVC Capital Partners ('CVC') and Hartenberg Holding ('Hartenberg'), is pleased to announce the acquisition of the Bristol Centre for Reproductive Medicine (BCRM). This internationally recognized fertility centre, located in  Bristol, the largest city in South West England and a vital economic and healthcare hub for the region,  represents a further step in FutureLife’s growth strategy, expanding its mission to provide best-in-class, patient-centric reproductive care to even more individuals and families.

BCRM has been a cornerstone of fertility services in the Bristol region for over 40 years. Originally established as a joint research project between the University of Bristol and Southmead Hospital, BCRM transitioned to an independent clinic in 2018. Offering both private and NHS-funded treatments to over 1000  patients each year. BCRM operates from its state-of-the-art facility in Bristol’s Aztec West, with additional satellite clinics in Bath and Cardiff. Grant Thornton acted as advisors to BCRM on this transaction.

Francisco Lobbosco, CEO of FutureLife, stated: "We are delighted to welcome BCRM to the FutureLife Group. BCRM’s strong reputation for advanced fertility care and its holistic, compassionate approach align seamlessly with our mission statement. Together, we are committed to delivering exceptional success rates and helping more individuals realize their dream of parenthood."

"The UK is a key market for us, and BCRM’s addition perfectly complements our presence at CRGH in central London, extending our reach into the West Country. Our approach focuses on harmonizing best practices across our clinics, while preserving each clinic's clinical autonomy and strong local identity."

Dr Valentine Akande, Director of BCRM:

"Joining the FutureLife Group marks a pivotal moment for BCRM, enabling us to tap into the strategic resources and expertise of a leading international network. This partnership will allow us to enhance our services and expand our reach while continuing to deliver the exceptional, patient-centred care that has defined us for over 40 years.

Our alignment with FutureLife's values of medical excellence and innovation reassures us that this collaboration will support the clinic’s growth while maintaining our focus on personalized treatment. We are excited about the future and confident this move will further strengthen our ability to help more people achieve their dream of starting or growing their families."

About FutureLife

FutureLife is one of the leading European providers of IVF, fertility treatments and related genetic services. With 40+ well-invested clinics, in 8 countries, employing more than 1,500 specialists performing in excess of 55,000 IVF cycles annually, as well as a series of gynaecological and surgical treatments.

In addition to its fertility clinic portfolio, FutureLife also operates two hospitals in the Czech Republic and the GNT Lab, one of the largest and most modern genetic laboratories in Europe and enables the group to meet the demand for genetic services with speed and efficiency, raising the level of care provided to the group’s patients.

The team at FutureLife believe in a world where everyone has the freedom to create a family and adopt an evidence-based approach to the innovation of treatment strategies, with a mission statement focused on ethics and standards. 

FutureLife Group operate two fertility clinics in London, under the renowned CRGH brand, purchased in 2022. The group is also focused on additional acquisitions in a number of other key European geographies.

FutureLife is co-owned by CVC and Hartenberg. www.futurelifegroup.com

 

Press contacts

For FutureLife:

Jane Exon

pressoffice@futurelifegroup.com